News & Updates

SB17, a proposed ustekinumab (UST) biosimilar, demonstrates comparable efficacy, safety, and pharmacokinetics (PK) to the reference drug, as well as lower immunogenicity up to week 28, among individuals suffering from moderate-to-severe psoriasis, according to a study.

For individuals with difficult-to-treat hypertension who are struggling with three separate medications, a single pill that combines four blood pressure (BP)-lowering drugs may help with BP control, as shown in the phase III QUADRO trial.

Initiation of sodium-glucose cotransporter-2 (SGLT-2) inhibitors results in a 35-percent reduced risk of dementia compared with dipeptidyl peptidase-4 (DPP-4) inhibitors in individuals with type 2 diabetes (T2D) aged 40–69 years, according to a study. In addition, greater benefits are seen with longer treatment duration.

Treatment with tapinarof cream 1% once daily demonstrates significant efficacy with a favourable safety profile among adults and children with moderate-to-severe atopic dermatitis (AD), a study has shown.

Use of dupilumab effectively lowers the risk of atopic march progression as opposed to conventional immunomodulatory therapies in paediatric patients with atopic dermatitis (AD), reports a recent study.